Virongy Biosciences Expands Prince William County, Virginia, Operations
05/18/2022
The company recently relocated to occupy over 2,000 square feet of the Northern Virginia Bioscience Center, where it will begin to develop new diagnostic technologies to monitor and quantify SARS-CoV-2 variants and other viral pathogens.
“Virongy Biosciences Inc. chose Virginia as its company location mainly because it is inside the rapid-growing biotech park of Prince William County, and right beside the Science and Technology Campus of George Mason University,” said Virongy’s Chief Scientific Officer Brian Hetrick.
The Virginia Economic Development Partnership (VEDP) worked with Prince William County to secure the project for Virginia and will support Virongy’s job creation through the Virginia Jobs Investment Program (VJIP), which provides consultative services and funding to companies creating new jobs in order to support employee recruitment and training activities. As a business incentive supporting economic development, VJIP reduces the human resource costs of new and expanding companies. VJIP is state-funded, demonstrating Virginia’s commitment to enhancing job opportunities for citizens.
“Virongy’s expansion in Prince William County reinforces the region’s robust industry talent, world-class education institutions, and advanced culture of innovation that supports the company’s mission,” said Secretary of Commerce and Trade Caren Merrick. “We thank Virongy for creating valuable jobs while improving the health of our communities, and look forward to its continued growth in Virginia.”
Established in 2014, Virongy focuses on creating cutting-edge technologies in virology, viral vector-based gene therapy, virus-host cell biology, and viral immunology. The company develops new technologies that can be used for scientific discoveries, clinical diagnostics, and disease treatment. Virongy has discovered and developed key technologies and products including rapid quantitative COVID-19 neutralizing antibody test, Infectin, Cellment, HIV Rev-dependent Lentiviral Vector, and HIV drug and neutralizing antibody discovery technologies. The company’s mission is to provide scientists and clinicians with innovative technologies for studying viruses and viral vectors, and to provide virological services that meet the highest academic and industry standards, facilitating scientific discoveries, clinical diagnostics, and disease treatment.
Project Announcements
Northern Ireland-Based Almac Group Expands Montgomery County, Pennsylvania, North American Headquarters
07/05/2022
Precision Planting Plans Morton, Illinois, Operations Center
07/05/2022
HHO Carbon Clean Systems Plans McCracken County, Kentucky, Production Plant
07/05/2022
Toast Establishes Nashville, Tennessee, Configuration Complex
07/05/2022
H-E-B Expands Temple, Texas, Distribution Operations
07/05/2022
Peerless Products Establishes Nevada, Missouri, Facility
07/02/2022
Most Read
-
Area Development’s 17th Annual Shovel Awards Recognize State and Local Economic Development Efforts — First Two Platinum Shovels Awarded
Q2 2022
-
In Focus: Demand for Industrial Land Surges
Q2 2022
-
The 2021 Top States for Doing Business Reflect Their Locational Advantages
Q3 2021
-
Five Ways for Manufacturers to Manage Global Market Volatility
Q2 2022
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
The Evolution of the Megasite
Q2 2022
-
Putting Your Best Foot Forward: Presentation of Incentives Information to the Media
Q2 2022